ReviewClinical microbiology reviews2015
Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak.
Review in Clinical microbiology reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Activation of thousands of genes in the lungs and kidneys by sepsis is countered by the selective nuclear blockade.Frontiers in immunology · 2023Article
- Biodefence research two decades on: worth the investment?The Lancet. Infectious diseases · 2021Review
- How To Prepare for the Unexpected: a Public Health Laboratory Response.Clinical microbiology reviews · 2021Review
- Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease.Journal of virology · 2019Article
- Budding of Ebola Virus Particles Requires the Rab11-Dependent Endocytic Recycling Pathway.The Journal of infectious diseases · 2018Article
- Autophagy-Associated Proteins Control Ebola Virus Internalization Into Host Cells.The Journal of infectious diseases · 2018Article
- Animal models for filovirus infections.Zoological research · 2018Review
- Generation of therapeutic antisera for emerging viral infections.NPJ vaccines · 2018Article
- Ebola virus requires a host scramblase for externalization of phosphatidylserine on the surface of viral particles.PLoS pathogens · 2018Article
- Antiviral activity of quercetin-3-β-O-D-glucoside against Zika virus infection.Virologica Sinica · 2017Article
- T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection.Emerging microbes & infections · 2017Article
- Article
- Contrasting academic and lay press print coverage of the 2013-2016 Ebola Virus Disease outbreak.PloS one · 2017Article
- One Health: Addressing Global Challenges at the Nexus of Human, Animal, and Environmental Health.PLoS pathogens · 2016Article
- Prophylactic Efficacy of Quercetin 3-β-O-d-Glucoside against Ebola Virus Infection.Antimicrobial agents and chemotherapy · 2016Article
- Engineered Mesenchymal Cells Improve Passive Immune Protection Against Lethal Venezuelan Equine Encephalitis Virus Exposure.Stem cells translational medicine · 2016Article
- Approved Antiviral Drugs over the Past 50 Years.Clinical microbiology reviews · 2016Review
- Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection.Scientific reports · 2016Article
- Two-mAb cocktail protects macaques against the Makona variant of Ebola virus.Science translational medicine · 2016Article
- Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
The 2014-2015 outbreak of Ebola virus (EBOV), originating from Guinea, is now responsible for the infection of >20,000 people in 9 countries. Whereas past filovirus outbreaks in sub-Saharan Africa have been rapidly brought under control with comparably few cases, this outbreak has been particularly resistant to containment efforts. Both the general population and primary health care workers have been affected by this outbreak, with hundreds of doctors and nurses being infected in the line of duty. In the absence of approved therapeutics, several caregivers have turned to investigational new drugs as well as experimental therapies in an effort to save lives. This review aims to summarize the candidates currently under consideration for postexposure use in infected patients during the largest EBOV outbreak in history.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.